Evidence map›Paper›PMID 39472908›Full record

ArticleGenome medicine2024

Cardiomyopathies in 100,000 genomes project: interval evaluation improves diagnostic yield and informs strategies for ongoing gene discovery.

Katherine S Josephs, Eleanor G Seaby, Philippa May, Pantazis Theotokis, Jing Yu, Avgi Andreou, Hannah Sinclair, Deborah Morris-Rosendahl, Ellen R A Thomas, Sarah Ennis and 2 more

Abstract read
In one paragraph

Article in Genome medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Katherine S JosephsNational Heart and Lung Institute, Imperial College London, London, UK. kjosephs@imperial.ac.uk.
Eleanor G SeabyGenomic Informatics Group, Faculty of Medicine, University of Southampton, Southampton, UK.
Philippa MayRoyal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Pantazis TheotokisNational Heart and Lung Institute, Imperial College London, London, UK.
Jing YuThe Innovation Building, Novo Nordisk Research Centre Oxford, Oxford, UK.
Avgi AndreouSSt George's University Hospitals NHS Foundation Trust, St George's University of London, London, UK.
Hannah SinclairGuy's and St Thomas' NHS Foundation Trust, London, UK.
Deborah Morris-RosendahlNational Heart and Lung Institute, Imperial College London, London, UK.
Ellen R A ThomasGenomics England, London, UK.
Sarah EnnisGenomic Informatics Group, Faculty of Medicine, University of Southampton, Southampton, UK.
Angharad M Roberts *National Heart and Lung Institute, Imperial College London, London, UK.
James S Ware *National Heart and Lung Institute, Imperial College London, London, UK.

Funding

British Heart Foundation FS/CRLF/21/23011
6 · The paper itself

Abstract

backgroundCardiomyopathies are clinically important conditions, with a strong genetic component. National genomic initiatives such as 100,000 Genome Project (100KGP) provide opportunity to study these rare conditions at scale beyond conventional research studies.

methodsWe present the clinical and molecular characteristics of the 100KGP cohort, comparing paediatric and adult probands with diverse cardiomyopathies. We assessed the diagnostic yield and spectrum of genetic aetiologies across clinical presentations. We re-analysed existing genomic data using an updated analytical strategy (revised gene panels; unbiased analyses of de novo variants; and improved variant prioritisation strategies) to identify new causative variants in genetically unsolved children.

resultsWe identified 1918 individuals (1563 probands, 355 relatives) with cardiomyopathy (CM) in 100KGP. Probands, comprising 273 children and 1290 adults, were enrolled under > 55 different recruitment categories. Paediatric probands had higher rates of co-existing congenital heart disease (12%) compared to adults (0.9%). Diagnostic yield following 100KGP's initial analysis was significantly higher for children (19%) than for adults (11%) with 11% of diagnoses overall made in genes not on the existing UK paediatric or syndromic CM panel. Our re-analysis of paediatric probands yields a potential diagnosis in 40%, identifying new probable or possible diagnoses in 49 previously unsolved paediatric cases. Structural and intronic variants accounted for 11% of all potential diagnoses in children while de novo variants were identified in 17%.

conclusions100KGP demonstrates the benefit of genome sequencing over a standalone panel in CM. Re-analysis of paediatric CM probands allowed a significant uplift in diagnostic yield, emphasising the importance of iterative re-evaluation in genomic studies. Despite these efforts, many children with CM remain without a genetic diagnosis, highlighting the need for better gene-disease relationship curation and ongoing data sharing. The 100KGP CM cohort is likely to be useful for further gene discovery, but heterogeneous ascertainment and key technical limitations must be understood and addressed.

Indexed as

CardiomyopathiesAdolescentAdultChildChild, PreschoolFemaleGenetic Predisposition to DiseaseGenetic TestingGenome, HumanGenomicsHumansInfantMaleMiddle AgedYoung Adult100,000 Genomes ProjectCardiomyopathyGenetic diagnosisGenome sequencingPaediatric

Identifiers

PMID39472908
PMCPMC11520845

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.